American Oncology Network | Genesis Cancer and Blood Institute

Research site

(Unclaimed)

Location

133 Harmony Park Cir, Hot Springs, Arkansas, United States of America

Site insights

Top conditions

Top treatments

Cyclophosphamide

Sacituzumab

Atezolizumab

Pembrolizumab

LY2835219

Doxorubicin

SBP-101

BMS-986489

Tiragolumab

BMS-986012

Parent organization

This site is a part of American Oncology Network

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 13 total trials

Locations recently updated

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer...

Enrolling

Lymphoma, Large B-Cell, Diffuse

Drug: Prednisone

Drug: Cyclophosphamide

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (I...

Active, not recruiting

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Drug: Domvanalimab

Drug: Zimberelimab

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting

Cytochrome P-450

Antineoplastic Agents, Hormonal

Drug: Placebo for Abemaciclib

Drug: Abiraterone

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with...

Enrolling

Extensive-Stage Small Cell Lung Cancer

Drug: Carboplatin

Drug: Etoposide

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor...

Enrolling

EGFR Inhibitor-associated Rash

Drug: ATR04-484

Drug: Vehicle

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3)

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved...

Enrolling

Large B-cell Lymphoma

Drug: Fludarabine

Genetic: cemacabtagene ansegedleucel

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Enrolling

Advanced Melanoma

Drug: EIK1001

Drug: Pembrolizumab (KEYTRUDA® )

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or with...

Enrolling

Pancreatic Cancer Metastatic

Pancreatic Cancer Stage IV

Drug: Gemcitabine

Drug: Nab-paclitaxel

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Active, not recruiting

Triple Negative Breast Cancer

PD-L1 Positive

Drug: Pembrolizumab

Drug: Carboplatin

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Active, not recruiting

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel